New hope for hodgkin lymphoma patients unable to tolerate chemo
NCT ID NCT05977673
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called tislelizumab in people with newly diagnosed Hodgkin lymphoma who are not able to receive standard chemotherapy. The goal is to see if the drug can shrink or control the cancer. About 28 participants will take part in this phase 2 trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
A.O. SS. Antonio e Biagio e Cesare Arrigo, S.C. Ematologia
RECRUITINGAlessandria, IT, Italy
Contact Email: •••••@•••••
Contact
-
Divisione di Oncologia e dei Tumori immuto-correlati, Centro Di Riferimento Oncologico Di Aviano
RECRUITINGAviano, Italy
Contact Email: •••••@•••••
Contact
-
Ematologia, Fondazione IRCCS Istituto Nazionale Dei Tumori
RECRUITINGMilan, Italy
Contact Email: •••••@•••••
Contact
-
Istituto Ematologia -Dipartimento di Medicina Traslazionale e di Precisione, Azienda Ospealiero Universitaria Policlinico Umberto I
RECRUITINGRoma, Italy
Contact Email: •••••@•••••
Contact
-
Istituto di Ematologia L. e A. Seràgnoli, AOU Policlinico S. Orsola-Malpighi
RECRUITINGBologna, Italy
Contact Email: •••••@•••••
Contact
-
Oncoematologia, Azienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello
NOT_YET_RECRUITINGPalermo, Italy
Contact Email: •••••@•••••
Contact
-
Oncologia, IRCCS Istituto Nazionale Tumori Fondazione Pascale
RECRUITINGNaples, Italy
Contact Email: •••••@•••••
Contact
-
SC Ematologia, Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia
RECRUITINGBrescia, Italy
Contact Email: •••••@•••••
Contact
-
U.O di Oncologia Medica ed Ematologia, Humanitas Research Hospital
RECRUITINGRozzano, Italy
Contact Email: •••••@•••••
Contact
-
Unità di Ematologia e TMO - Unità Linfomi, Ospedale San Raffaele
RECRUITINGMilan, Italy
Contact Email: •••••@•••••
Contact